Abstract 624P
Background
Most cancer immunotherapy research focuses on gene-level expression, often bypassing the key role of alternative splicing in producing various isoform transcripts. Alternative splicing contributes significantly to tumor heterogeneity, progression, and therapy response1-3. Understanding these dynamics is paramount for advancing personalized treatment strategies.
Methods
1. Data Integration - Integrated multi-omics data from diverse tumor types. - Focused on immune cells within the tumor microenvironment. 2. Sample collection - Gathered data from both pre- and post-immunotherapy treated patients. - Included clinical response details for comprehensive insights. 3. Isoform analysis - Constructed a single-cell isoform atlas capturing the landscape of alternative splicing events and isoform expression profiles across a vast array of cancers. - Investigated patterns of isoform diversity/plasticity: - Within and between different cancer types. - Between pre- and post-treatment scenarios. - Among responders vs. non-responders.
Results
Pan-cancer isoform signatures - For each cancer type and at the pan-cancer level, the isoform patterns of immune cell types linked with oncogenic processes between (i) healthy and cancer; (ii) pre- and post-treatment; (iii) immunotherapy responders and non-responders.
Conclusions
Our pan-cancer single-cell isoform atlas offers a groundbreaking perspective on isoform dynamics in cancer immune environment, enriching our comprehension of tumor intricacies and bolstering efforts toward precision oncology for individualized patient care.
References: 1. Climente-González, H., Porta-Pardo, E., Godzik, A. & Eyras, E. The Functional Impact of Alternative Splicing in Cancer. Cell Reports 20, 2215-2226 (2017). https://doi.org:https://doi.org/10.1016/j.celrep.2017.08.012.
2. Zhang, Y., Qian, J., Gu, C. & Yang, Y. Alternative splicing and cancer: a systematic review. Signal Transduction and Targeted Therapy 6, 78 (2021). https://doi.org:10.1038/s41392-021-00486-7
3. Bonnal, S. C., López-Oreja, I. & Valcárcel, J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nature Reviews Clinical Oncology 17, 457-474 (2020). https://doi.org:10.1038/s41571-020-0350-x
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Pan.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract